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HIV latency constitutes the main barrier for clearing HIV infection from patients. Our inability to
recognize and isolate latently infected cells hinders the study of latent HIV. We engineered two HIV-
based viral reporters expressing different ﬂuorescent markers: one HIV promoter-dependent marker for
productive HIV infection, and a second marker under a constitutive promoter independent of HIV
promoter activity. Infection of cells with these viruses allows the identiﬁcation and separation of latently
infected cells from uninfected and productively infected cells. These reporters are sufﬁciently sensitive
and robust for high-throughput screening to identify drugs that reactivate latent HIV. These reporters can
be used in primary CD4 T lymphocytes and reveal a rare population of latently infected cells responsive
to physiological stimuli. In summary, our HIV-1 reporters enable visualization and puriﬁcation of latent-
cell populations and open up new perspectives for studies of latent HIV infection.
& 2013 Published by Elsevier Inc.Introduction
The discovery of effective therapies against HIV, called highly
active antiretroviral therapy (HAART), has transformed a once
deadly disease into a life-long chronic condition (Palella et al.,
1998). By hijacking the viral machinery during infection, HAART
effectively reduces infection to undetectable levels. Nonetheless,
complete suppression of viral replication by HAART cannot clear
HIV infection and the virus reappears rapidly upon treatment
interruption (Richman et al., 2009). HIV persists under HAART in a
rare population of long-lived, latently infected cells. In addition,
the persistence of latent reservoirs feeds an inﬂammatory-like
state that contributes to the development of accelerated aging
phenotypes and accompanying age-related diseases in the HAART-
treated HIV-positive population (Deeks, 2011).
HIV latency is deﬁned as a state in which proviral DNA is
integrated irreversibly in the cell genome, but expression of the
viral genes is silenced due to a repressed state of the viral LTR
promoter (Hakre et al., 2011). Alternatively, HIV latency can be duelsevier Inc.
irology and Immunology,
: +1 415 826 8449.to blockade of virus production at any step (Colin and Van Lint,
2009).
Latently infected cells are extremely rare in patients and carry
silent integrated HIV genomes that produce no detectable virus.
Current technologies do not allow the identiﬁcation and puriﬁca-
tion of live infected cells that do not express any HIV proteins.
Latency has therefore been studied “a posteriori” via reactivation
of expression of the latent provirus. This type of analysis has
allowed the quantiﬁcation of latent cells in different lymphoid
populations and the testing of different drugs that reactivate latent
HIV. However, our inability to identify latently infected cells before
reactivation has precluded a full understanding of the latency
process.
In this study, we present a novel tool that uses ﬂuorescent
reporter-based HIV constructs expressing two ﬂuorescent pro-
teins, one dependent and one independent of HIV promoter
activation state. This reporter system allows the detection and
puriﬁcation of a cell population of latently infected cells that can
be reactivated by physiological and pharmacological stimulation.
We show that this system can be used in various cell lines to
identify and purify polyclonal populations of latently infected cells.
Such populations can be used in high-throughput assays while
overcoming the clonal-derived biases of current in vitro systems.
We also show that these viral constructs are suitable for the study
of latency in human primary CD4+ T cells.
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Dual-color viruses allow direct labeling of live HIV latently
infected cells
To identify latently infected cells prior to reactivation, we
designed two HIV-1-based lentiviral constructs in which LTR
expression is monitored by production of a ﬂuorescent protein
while another independent transcriptional unit expresses a spec-
trally distinct ﬂuorescent protein under the control of an inde-
pendent promoter. To construct the ﬁrst clone, we used the 89.6/
DNE/SFG reporter in which nef is replaced by a Spleen Focus
Forming Virus (SFFV)-promoter-driven enhanced green ﬂuores-
cent protein (EGFP; Fig. 1B) (Carter et al., 2010). This clone has an
env deletion, which limits infection to a single round. We used a
sequence- and ligation-independent cloning (SLIC) (Li and Elledge,
2012) strategy to reconstitute the nef ATG sequence and replace
the remainder of the nef open reading frame with the sequence of
a red ﬂuorescent protein, mApple (Shaner et al., 2008) (Fig. 1B,D);
this construct was named 89.6/DNE/mApple/SFG (89mASG).
The second construct was derived from the HXB2-based R7/3
clone bearing EGFP in place of nef and an env deletion (Jordan
et al., 2003) (Fig. 1C). We used the SLIC technique to insert the
whole EF1α-mCherry transcriptional unit between the EGFP and
the virus 3′ LTR (Fig. 1C,D). We named this construct R7/E-/GFP/
EF1a-mCherry (R7GEmC).
To test the potential of these viral reporters to differentiate
latent from actively infected and uninfected cell populations, we
infected Jurkat T cells with our new constructs (Fig. 1E,F). After
infection, a double-positive population expressing the HIV promoter-
dependent reporter and the HIV promoter-independent reporter
(SFFV or EF1α promoter) emerged for both viruses (Fig. 1E,F). In
addition, we detected a single-positive population expressing only
the HIV promoter-independent reporter, green for 89mASG (Fig. 1E)
and red for R7GEmC (Fig. 1F).
To conﬁrm that the single-positive cells expressing only the
non-HIV promoter-driven reporter were latently infected cells, we
sorted the GFP-only-positive and mCherry-only-positive cells from
the 89mASG-infected and R7GEmC-infected pools, respectively, as
well as the double-positive (productively infected) and the
double-negative (uninfected) cells for each pool (Fig. 1G, H; left).
The single-positive and double-negative cells were expanded
in vitro after sorting, whereas the double-positive cells did not
expand efﬁciently and largely died after sorting (especially the
89mASG-infected; not shown), as predicted by the cytotoxic
properties of active viral infection (Cummins and Badley, 2010).
The different sorted populations were analyzed for viral DNA, RNA
and protein content. Whereas the double-negative cells had low
HIV DNA levels, the single-positive cells had DNA amounts
comparable to those of double-positive cells (Fig. 1I) but expressed
no detectable viral mRNA (Fig. 1J) or protein (Fig. 1K). Only the
double-positive population expressed viral transcripts and pro-
teins. These results are consistent with our model that cells
expressing only the non-HIV promoter-driven reporter were
latently infected cells
Cells Enriched for HIV promoter independent expression contains
an HIV genome that can be reactivated
To estimate the fraction of single-positive cells that can be
reactivated in terms of HIV expression, we treated the puriﬁed
cells with drugs reported to reactivate latent HIV, including tumor
necrosis factor (TNF)-α (Jordan et al., 2003); prostratin, a protein
kinase C (PKC) activator (Williams et al., 2004); and suberoylani-
lide hydroxamic acid (SAHA) (Contreras et al., 2009), a non
selective histone deacetylase (HDAC) inhibitor. All drugs increasedexpression of HIV promoter-dependent reporter (Fig. 2A,B top, C,D).
Testing of drug combinations that act on different pathways showed
maximal reactivation in response to combined SAHA and prostratin
treatment, as previously reported by others (Reuse et al., 2009).
In both 89mASG- and R7GEmC-infected latent populations, we
observed spontaneous reactivation of latency in the absence of
activating molecule, likely reﬂecting the bi-stable nature of HIV
expression (Weinberger et al., 2008).
Due to the integration site of the provirus or the cell state, it is
possible that some latently infected cells were classiﬁed as double-
negative because of silencing of both the HIV promoter and the
SFFV or EF1α promoter. To address this possibility, we treated the
double-negative populations with the same drugs (Fig. 2A and B,
bottom) and found only very limited reactivation, affecting o1%
of the population. This implies that the silent HIV provirus in the
double-negative population has little to no ability to reactivate in
response to stimulation of latent HIV-reactivating cell pathways.
This two-color latency model, which relies on de novo cell
infection, can easily be transferred to study the biology of latency
in a wide variety of cell types. As an example, we infected and
sorted two additional T-cell lines commonly used in HIV biology,
SupT1 (Fig. 2E) and A301 (Fig. 2F). Comparison of the sorted latent
populations from those cell lines and Jurkat T cells with an
extensive panel of HIV-reactivating drugs—including TNFα, pros-
tratin, SAHA, phorbol myristate acetate (PMA), bryostatin, hexam-
ethylbisacetamide (HMBA), and phytohemagglutinin type-M
(PHA-M) (Fig. 2G)—revealed signiﬁcant differences in drug-inde-
pendent and drug-dependent reactivation rates. This observation
supports the concept that use of a non-clonal, non-stimulus-
biased experimental system to study HIV latency, as exempliﬁed
by these new viruses, adds signiﬁcance and robustness to the
study of mechanisms for reactivation from latency.Two-color HIV latency model can be used for high-throughput
screening
Next, we tested the power of this novel HIV latency experi-
mental system to identify novel drugs that reactivate latent HIV in
a high-throughput format. We plated 5,000 GFP-only-positive cells
of 89mASG-infected Jurkat T cells in each well of 384-well plates,
coated with a protein solution (Cell-tak) to induce cell attachment
and efﬁcient imaging. Preliminary experiments indicated that this
protocol yielded the lowest background reactivation and the
highest dynamic range (up to 75% cell reactivation with the most
effective drug combinations) (data not shown). Cells were treated
with 1120 individual compounds from the Tocriscreen biologically
active compound library at 30 mM for 24 h (drug combinations are
shown in Fig. 2A,B) before they were stained with Hoechst. Next,
we imaged each well and quantiﬁed total red ﬂuorescence
(indicative of reactivated virus) and total blue ﬂuorescence
(Hoechst-stained nuclei) (Fig. 3A).
For most compounds in each plate, we found a uniform
distribution of signal around the median of the negative controls,
while a notably higher red signal for positive controls that were
added in control wells on each plate (TNF, SAHA, Prostratin and
their combinations as described in the previous section) (Fig. 3A).
We also identiﬁed a group of drugs that reactivated latent HIV,
although to a lesser extent than the positive controls SAHA and
prostratin (Suppl. Table 1). Some, such as resveratrol (Krishnan
and Zeichner, 2004), and genistein (Gozlan et al., 1998), have been
reported previously to reactivate latent HIV, thereby validating
this experimental system. In addition, a number of unanticipated
and novel drug classes emerged from the analysis, such as those
that act on epidermal growth factor receptor (EGFR), dopamine
and serotonin receptors.
V. Calvanese et al. / Virology 446 (2013) 283–292 285Next, using the 89mASG and R7GEmC constructs and FACS
analysis, we further tested a small group of commercially available
drugs and analogs not present in the Tocris library that act on
similar pathways, to assess their involvement in HIV latencyFig. 1. Two-color viruses identify a population of latently infected cells. (A) Diagram o
classical single reporter virus bearing the reporter gene in the nef ORF. (B) In the 89mASG
upstream of the transcriptional unit in the position of the nef ATG (see D). (C) In the R7
was inserted downstream. (D) Alignment of regions of interest (from the end of env to
(U39362.2 and NC001802), the starting plasmid and ﬁnal constructs for each of the H
reporter in the nef ORF, the promoter (SFFV or EF1α, respectively) and the second repor
3 days post-infection, with the indicated titers of 89mASG (E) and R7GEmC (F). (G,H) FAC
infection. Double-negative (uninfected), double-positive (actively infected) and single-po
viral strains. Fluorescence microscopy images of 89mASG (G, right) and R7GEmC (H, righ
populations, using the primer-probe combination #E for the HIV-1 gag gene and RNAseP
singly- (SS) env and multiply-spliced (MS) tat/rev common regions (#E, F, and G; Supp
proteins vif and gag and the endogenous protein α-actin in the sorted Jurkat populationmaintenance. Cells were treated with the dopamine receptor
agonist apomorphine, used clinically as an emetic and for male
impotence, and the D2-receptor-speciﬁc analog R-()-propylnor-
apomorphine (PNA). In addition, we tested the serotonin receptorf the derivation of two-color viruses from the original strains, with a scheme of a
construct, EGFP is under the control of the SFFV promoter and mApple was added
GEmC construct, GFP replaces nef and a whole transcriptional unit (EF1α-mCherry)
the 3′LTR) of the original 89.6 and HXB2 strains deposited in the NCBI database
IV clones 89mASG (D, top) and R7GEmC (D, bottom). Insertion points of the ﬁrst
ter, followed by the end of nef and 5′LTR. (E,F) Cytometric analysis of Jurkat T cells
S analysis of 89mASG (G, left) and R7GEmC (H, left) Jurkat T cells sorted 5 days post-
sitive (latently infected, expressing GFP- or mCherry-only) cells are shown for both
t) infected Jurkat T cells. (I) qPCR quantiﬁcation of proviral DNA in the sorted Jurkat
for normalization. (J) qPCR quantiﬁcation of viral transcripts of unspliced (US) gag,
l. Table 2), normalized for cell GAPDH. (K) Western blot quantiﬁcation of the HIV
s.
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receptor antagonists AG555 and AG18 (candidates for speciﬁc cancer
treatments), the resveratrol analogs piceatannol and pterostilbeneFig. 2. Latently infected cells respond to reactivating drugs. (A–D) Five days after sorting
and R7GEmC (B,D) Jurkat T cells were treated with 10 ng/ml TNFα, 5 μM prostratin or 2.
treatment (A,B) and histogram quantiﬁcation of percent population in the active gate
treatments. Po0.01 for combination vs. single treatments, except for R7GEmC prostrat
infected with 20 ng p24 of 89mASG (E) or R7GEmC (F) virus. (G) A larger panel of late
positive Jurkat, SupT1 and A301 cells. Histograms show quantiﬁcation of the percent
treatments. Po0.01, compared to DMSO 0.1% control for all treatments, except for: SAH
A301-R7GEmC, Po0.05 in Jurkat-R7GEmC; Bryostatin 30 μM (Po0.05) in A301-R7GEm
R7GEmC, Po0.05 in Jurkat-R7GEmC and SupT1-89mASG; PHA-M n.s in A301-89mASG(antioxidants with broad and incompletely understood mechanisms
of action), the adenosine reuptake inhibitors dilazep and dipyrida-
mole (used as vasodilators and platelet anti-aggregants), the cdc25, expanded single-positive (latent) and double-negative (uninfected) 89mASG (A,C)
5 μM SAHA, alone or in combination, as indicated. FACS analysis of a representative
for three different experiments (C,D). Po0.001, compared to DMSO control for all
in vs. prostratin+SAHA (Po0.05). (E,F) FACS analysis of SupT1 and A301 cell lines,
nt HIV-reactivating drugs was used at indicated concentrations on sorted, single-
population in the active (red) gate. Data indicate mean7SD for three different
A 0.1 μM not signiﬁcant (n.s.) in all combinations; SAHA 0.3 μM n.s. in SupT1 and
C; HMBA 0.3 mM n.s. in all combinations; HMBA 1 μM n.s. in A301 and SupT1-
and Po0.05 in A301-R7GEmC.
Fig. 3. High-throughput screening identiﬁes new reactivator drugs using two-color HIV constructs. Sorted 89mASG-infected, GFP-only-positive Jurkat cells were used to test the
Tocriscreen drug library for latent HIV reactivation (see Methods). (A) Dot plot showing quantiﬁcation of total blue area (Hoechst 33342 signal, total cell) against total red area (mApple
signal, reactivated HIV). Red dots indicate the position of untreated wells; the shaded area indicates the median72 SD of the red/blue area ratio for negative control wells. Green dots
indicate positive control wells, treated with 10 ng/ml TNFα, 5 μMprostratin or 2.5 μM SAHA and their combinations. Blue circle shows novel reactivators identiﬁed in the screening (see
Suppl. Table 1). (B) Validation of representative hits by FACS analysis. Apomorphine and its analog R-()-propylnorapomorphine (PNA), ritanserin, clozapin, AG555, AG18, piceatannol,
pterostilbene, dilazep, dipyridamole, terreic acid (TA), simvastatin and NSC95397 were used to validate hits and pathways identiﬁed by drug screening. Representative FACS plots of
sorted single-positive Jurkat T cells for both viruses. The red gate contains the reactivated cells. In the last plot on the right, NSC95397 treatment shows alteration of the ﬂuorescent
proﬁle by the drug ﬂuorescence. (C,D) Histogram plot of percent population in the reactivated cells gate (gray) for each treatment and percentage of cells in the live gate (light blue) for
sorted single-positive Jurkat T cells for 89mASG (C) and R7GEmC (D) reporters. Data shown as mean7SD for three different treatments. For each compound, a gray triangle between
the histograms indicates decreasing drug concentration (30, 10 and 3 μM). Treatments for which cell death was predominant are labeled TOXIC. Ritanserin 30 μM, clozapin 30 μM,
AG555 30, 10 and 3 μM, piceatannol 30 and 10 μM, pterostilbene 30 μM, dilazep 30 μM, TA 10 and 3 μM (Po0.01) and PNA 30 μM, piceatannol 3 μM, pterostilbene 10 μM, dipyridamole
30 μM (Po0.05) show signiﬁcant reactivation of the latent 89mASG virus compared to the DMSO control. Apomorphin 30 μM, PNA 30 μM, ritanserin 30 μM, clozapin 30 μM, AG555
30,10 and 3 μM, AG18 30,10 and 3 μM, piceatannol 30 and 10 μM, pterostilbene 30 10 and 3 μM, TA 10 μM (Po0.01) and PNA 10 μM, ritanserin 10 μM, piceatannol 3 μM, dilazep 30,10
and 3 μM, TA 3 μM (Po0.05) show signiﬁcant reactivation of the latent R7GEmC virus. (E) FACS analysis of drug treatments combined with 0.5 μM SAHA, 0.5 μMprostratin and 0.5 ng/
ml TNFα. Representative FACS plots of sorted GFP-only-positive Jurkat T cells for 89mASG treated with DMSO (control), SAHA (0.5 μM) alone or with terreic acid (10 μM) and dilazep
(30 μM). (F) Histogram plot of percent population of the sorted cells in the productive gate for each treatment at indicated concentrations (μM). Dilazep 30, 10 μM and piceatannol
10 μM show signiﬁcant (Po0.01) increase in reactivation 0.5 μM SAHA, 0.5 μM prostratin and 0.5 ng/ml TNFα as compared to the reactivation obtained with these three drugs alone.
TA also shows positive interaction with SAHA and prostratin at 10 μM (Po0.01) and with SAHA at 3 μM (Po0.05). AG555 interact enhances reactivation mediated by prostratin and
TNFα (Po0.01), whilst dipyridamole 30 and 10 μM shows signiﬁcant (Po0.05) positive interaction with prostratin only.
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()-terreic acid, and the HMG-CoA synthase inhibitor simvastatin
(Fig. 3B,C). Among these, PNA, ritanserin, clozapin, AG555, piceatan-
nol, pterostilbene, dilazep and terreic acid produced slight but
signiﬁcant reactivation activity in both the 89mASG (Fig. 3B,C) and
R7GEmC (Fig. 3B,D) single-positive latent populations. Other mole-
cules were ineffective (simvastatin) or had distinct effects in the two
HIV clones (apomorphin, AG18). In some cases, the intrinsic ﬂuores-
cence of the molecule produced clear artifacts or false positives
(see NSC 95397; Fig. 3B).
A recent study showed that the approved HDAC inhibitor SAHA
can reactivate HIV RNA expression in a subset of patients (Archin
et al., 2012). Thus, it might be of interest to identify compounds
that can potentiate HIV reactivation by SAHA or prostratin or TNFα.
Sorted latent-cell populations were co-treated for 24 h with low
levels of SAHA, prostratin and TNFα, and several effective, non-
toxic concentrations of the most promising compounds (Fig. 3E).
Interestingly, combining SAHA with terreic acid, dilazep or picea-
tannol (10 μM) strongly enhanced the effect of low SAHA concen-
trations on HIV latency on these cells; the same drugs showed a
latency reactivation effect greater than the sum of their individual
activities when combined with prostratin. TNFα combinations
showed positive interaction with AG555, dilazep and piceatannol,
but not with terreic acid, possibly indicating that the latter drug
acts on the same pathway as TNFα.
Two-color HIV constructs detect latency in primary T Cells
Studies of the basic biology of HIV latency have recently
emphasized the use of primary cell–based models in an effort to
more closely mimic the situation in patients. The use of primary
CD4+ T cells from human donors nonetheless remains a challenge,
due to low latency establishment rates and limited expansion
potential. Resting peripheral CD4+ T cells are generally refractory
to HIV infection and require pre-stimulation to achieve efﬁcient
infection. Furthermore, T-cell-receptor stimulation and IL2 and/or
IL7 supplementation (Bosque et al., 2011), which is needed for
expansion of these cells in culture and for permissive HIV infec-
tion, activate the latent HIV provirus, thereby making expansion of
latently infected cells unfeasible unless a transformed-like pheno-
type is induced (Yang et al., 2009).
Despite these limitations, a number of experimental model
system for HIV latency have been established in primary CD4+ T
cells (Hakre et al., 2012). We therefore tested our viral constructs
for their potential to generate a latent infection in primary CD4+ T
cells. Cells were activated with anti-CD3 and anti-CD28-coated
dynabeads for 48 h and infected with both viruses. We found that
both viruses infected activated CD4+ T cells efﬁciently, generating
an active infection as determined by expression of the HIV
promoter-dependent reporters mApple (for 89mASG)(Suppl.
Fig. 1), and GFP (for R7GEmC) (Fig. 4A,B). A very small population
of cells expressing only the latency-associated ﬂuorescent marker
was also generated in approximately 1 of 100 active infection
events. As the GFP signal in 89mASG-infected primary cells
was dim and difﬁcult to distinguish from uninfected cells, the
R7GEmC construct was used for additional experiments in primary
CD4+ cells.
We measured HIV proviral DNA and HIV gag in sorted
mCherry-only populations compared to uninfected and actively
infected sorted populations. Viral DNA was detected at high levels
in double-positive cells and slightly lower levels in mCherry-
positive cells (Fig. 4C). Interestingly, lower but still detectable
amounts of proviral DNA were also detected in double-negative
cells, indicating that some latent events might be found in this
population if EF1α promoter expression is also blocked. As pre-
dicted, the HIV gag protein was also detectable in the activelyinfected population, and absent in latent and uninfected popula-
tions (Fig. 4D).
We next evaluated the extent to which mCherry-only-positive
populations could be reactivated by further stimulation. After
sorting the three populations of mCherry-only-expressing, GFP-
positive, and double-negative cells, cells were treated with anti-
CD3/28-coated beads to reactivate the latent provirus (Fig. 4E).
The latent population responded to this treatment with a 15–18%
increase in cells expressing GFP. The double-negative population
also responded to a lesser extent, with 0.5–2% reactivation.
A population of very bright mCherry-only cells did not respond
to treatment, suggesting aberrant integration events or non-
reactivatable latent provirus. A subset of less-bright mCherry-
only-positive cells also responded to prostratin and SAHA treat-
ment (Fig. 4F), suggesting that this population of primary CD4+ T
cells contains latently infected, reactivatable cells.
HIV latency in vivo is reported to result, in part, from pre-
integration latency, whereby unintegrated proviral DNA (after full
retrotranscription) is maintained in a stable cytoplasmic form in a
quiescent cell, and can respond to cell activation by de novo
integration and productive infection (Pierson et al., 2002). To rule
out pre-integration latency, we infected activated CD4+ T cells with
R7GEmC in the presence of the HIV integrase inhibitor raltegravir
(Suppl. Fig. 2A). Under these conditions, we found no integration-
independent expression of the ﬂuorescent proteins after 3 days,
thereby excluding pre-integration latency as a major mechanism
in this primary-cell-infection model. In addition, raltegravir treat-
ment did not reduce viral reactivation in the mCherry-only-
positive population, indicating that all reactivatable latent cells
were in a post-integration latency stage (Suppl. Fig. 2B).Discussion
A major obstacle in the development of an eradication-based
cure for HIV is the virus' ability to establish latent infection (Trono
et al., 2010). As latent viruses are inactive and extremely rare
in vivo, the ability to detect and enrich for a latently infected cell
population would powerfully advance our understanding of the
mechanism of HIV latency. Here, we describe two HIV-reporter
systems that allow for the identiﬁcation and puriﬁcation of live,
latently infected cells and their separation from actively infected
and uninfected cells.
Using Jurkat and other cell lines, we show that puriﬁcation of
latently infected cells from a primary infected pool allows for the
study of HIV latency independent of cell clonality, insertion sites in
the genome, and reactivating stimuli. The dynamic range of
reactivation assays is also increased, due to the separation of
homogeneous latently infected from uninfected cells. This permits
the detection of novel compounds that reactivate latent HIV,
providing new possibilities for combination therapies.
A recent paper has reported a similar dual ﬂuorescence HIV
construct to study HIV latency. In this construct, a GFP marker was
inserted in the Gag gene leading to the synthesis and incorpora-
tion of a fusion Gag-GFP protein which is proteolytically released
in the mature virion and used to monitor HIV expression. A CMV-
mCherry cassette was added in place of nef to monitor integration
events (Dahabieh et al., 2013). This tool has similar applications to
the HIV reporter that we describe in this work, although the
presence of GFP in the virion limits the possibility of studying the
early kinetics of integration and HIV promoter activation. In
addition, the use of the CMV promoter which shows variable
activity in hematopoietic lineages and a high dependence on the
degree of CD4+ T cell activation, might not be optimal (Sirven et al.,
2001).
Fig. 4. Two-color viruses label a population of latently infected primary T cells. (A) FACS analysis of activated CD4+ T cells from two human donors (#1, #2) infected with
R7GEmC at indicated virus amounts. (B) Fluorescence microscopy image of infected CD4+ T cells showing mCherry-positive (latent, red) and GFP-positive (active, green) cells.
(C) qPCR quantiﬁcation of proviral DNA in the sorted populations, using primer-probe combinations for the HIV-1 gag gene and the RNAseP gene for normalization. Data
represent mean7SEM for three different donors. (D) Western blot quantiﬁcation of HIV gag and cell α-actin in sorted CD4+ T cell populations from pooled donors. (E) FACS
analysis of sorted CD4+ T cell populations from donors #1 and #2 after 48 h with anti-CD3/CD28-coated Dynabeads (αCD3/28) or left untreated (CTR). Right, histogram plot
for the mCherry-only population of each donor in which the treated proﬁle (green line) is overlaid on the untreated (gray shaded). (F) Dot plot of mCherry-only population
from three pooled donors treated with 10 ng/m, TNFα, 1 μM prostratin, 1 μM SAHA or anti-CD3/CD28-coated Dynabeads (1 bead/cell).
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infected cells require prestimulation with speciﬁc compounds or
cytokines to identify the infected population, and subsequentinduction of a latent state (Bosque and Planelles, 2009; Duverger
et al., 2012; Hakre et al., 2012). This experimental system skews
the study of latent HIV populations by restricting analysis to a
V. Calvanese et al. / Virology 446 (2013) 283–292290subset of latent infection events responsive to that compound and
able to overcome the cytotoxic effect of HIV reactivation. Our
constructs detect a population of latently infected cells regardless
of their responsiveness to the reactivation of cellular pathways,
and thus more closely approximates the establishment of latent
infection early in the viral life cycle prior to initiation of tat-
dependent HIV transcription.
Although our system overcomes the issues of clonality and
dependence on speciﬁc reactivation pathways, it does not detect
latent infection events that repress both the HIV and the EF1α or
SFFV promoters. Although this limitation could potentially skew
analysis of latent infection events, we detect lower levels of
proviral DNA in the double-negative population than in the
ﬂuorescent cells, indicating that the events that we missed are
relatively rare. In addition, a very small number of the potentially
latently infected cells in this population are responsive to phar-
macological reactivation, which implies that these double-
negative latent cells are incapable of, or refractory to, rebound of
the viral life cycle and may represents HIV proviruses that are
terminally silenced. In contrast, Dahabieh et al. observe a signiﬁ-
cant and robust of reactivation from latency in the sorted double-
negative population, possibly due to a subset of latent events in
their system that fails to activate the CMV promoter (Dahabieh
et al., 2013).
Our HIV latency model uses a replication-deﬁcient lentiviral
system that is easily pseudo-typed and packaged in a number of
ways, which facilitates its use for the study of latent infection
events in any cell population of interest. Our study focused on the
widely used Jurkat T-cell line; however, two other T cell-derived
cell lines, A301 and SupT1, can also be infected if the receptors and
co-receptors expressed are compatible with the viral envelope of
choice (in our experiments, a dual-tropic HIV gp160 derived from
a patient isolate (clone 92HT593.1) (Gao et al., 1996). Our system
can thus be potentially used in different cell types and candidate
reservoirs of the latent HIV pool.
The use of two viral clones on different cell lines allowed us to
observe a phenomenon of variable basal reactivation from latency
in the isolated latently infected populations. The vector R7GEmC
appears to have higher basal reactivation, which leads to a
tendency to double-positive cell accumulation upon re-
expansion from sorted mCherry-only cells. This basal reactivation
as well as the responsiveness to different drugs also varied among
the three tested cell lines. This instability might be a result of
selecting latent infection events early after infection, before long-
term maintenance processes have established, and might reﬂect
the bistable nature of HIV transcription, as described by Weinber-
ger et al. (Weinberger et al., 2008).
To demonstrate the potential of these dual-color viruses for
high-throughput applications such as drug discovery, we con-
ducted a small-scale high-throughput screen of constructs with a
biologically active compound library. Although none of the 1120
compounds tested showed higher reactivation potential than the
known latent HIV reactivators, we identiﬁed classes of clinically or
experimentally used drugs, not typically associated with the
biology of HIV latency, that produced small but signiﬁcant reacti-
vation of the provirus, such as drugs acting on neurotransmitter
receptors or Tyr kinases. In ﬂow cytometry assays of the sorted
latent-cell population, some of the identiﬁed drugs showed a
dose-dependent reactivation of latency; in combination with low
doses of the current leads for latent HIV reactivation (SAHA,
prostratin) they also revealed a synergistic effect that might be
exploited for research and as a therapeutic tool in current and
future clinical protocols.
For a preliminary validation in primary cells, we tested the HIV
latency model in activated CD4+ T cells. These cells contain the
main constituents of the latent HIV reservoir, such as central andtransitional memory CD4+ T cells. As reported (Baldauf et al.,
2012), resting CD4+ T cells are refractory to HIV infection, with few
or no ﬂuorescent cells when viruses are tested in freshly isolated
populations (not shown). Although we prestimulated cells with
anti-CD3/CD28-coated beads to boost infection levels, latent
infection rates remained very low, as is predicted for a fully
activated T cell. The mApple-only-expressing cells obtained from
infection of primary activated CD4+ cells had proviral DNA levels
similar to those of the double-positive population, but did not
express viral products such as p24. Only a small but measurable
part of the mApple-only population (o20%) responded to αCD3/
CD28 stimulation or to molecules that reactivate latent HIV in
other systems (SAHA, Prostratin). Importantly, we can detect a
small population of latently infected, reactivatable CD4+ T cells
after infection of activated T cells.
In conclusion, we present a powerful instrument to study HIV
latent infection. These new reporter viruses offer the advantage of
enabling detection and puriﬁcation of live, latent-HIV-infected
cells and to study the kinetics of latency establishment early upon
cell infection. This tool can further advance the study of HIV
latency and provide new routes to accelerate the quest for a
functional cure and eradication of HIV infection.Experimental procedures
Plasmid construction
HIV clones 89.6-DNE-SFG (donated by Dr. Kathleen Collins's
laboratory) and R7/E-/GFP were linearized by PCR using opposing
primers (see Suppl. Table 2, #A and B) in the position selected for
insertion (Fig. 1). mApple and the EF1a-mCherry sequences were
cloned in the respective plasmids by a modiﬁed SLIC technique
(Li and Elledge, 2012). Brieﬂy, inserts were PCR-ampliﬁed from
plasmid templates with primers that have a 20 bp 5′-overhang
complementary to the end sequences of the blunted plasmids (see
Suppl. Table 2, #C and D). DNA from all ampliﬁcations was
gel-puriﬁed, digested with 3′–5′ exonuclease (T4-polymerase,
Novagen, 30 min, 25 1C) and heat-inactivated (20 min, 75 1C).
Digested inserts and vectors for each construct were mixed at a
2:1 M ratio for complementary-end sequence annealing (20 min,
37 1C) and transformed in chemically competent Stbl-2 E. coli (Life
Technologies). Positive clones were resequenced entirely.
Virus production
HEK293 T cells were cotransfected with the viral plasmid clone
of interest and the env-encoding plasmid pSVIII-92HT593.1
(NARP), using Lipofectamine 2000 (Invitrogen). Medium (DMEM,
10% FBS) was changed 8 h post-transfection and collected at 72 h.
Virus supernatant was ﬁltered through a 0.45 μm-pore membrane,
concentrated by ultracentrifugation and stored at 80 1C. Virus
concentration was estimated by p24 titration (HIV-1 alliance p24
ELISA kit, Perkin-Elmer).
Cells and treatments
HEK293T, Jurkat, A301 and SupT1 cell lines were obtained from
ATCC. Suspension cells were cultured in RPMI 1640 supplemented
with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and
2 mM L-glutamine (PSG) (37 1C, 5% CO2). Peripheral blood from
healthy human donors was obtained from the Stanford Blood
Center and processed the day of collection. CD4+ T cells were
isolated with RosetteSep Human CD4+ T-Cell Enrichment Cocktail
(Stem Cell Technologies) and cultured in human cell medium
(HCM, RPMI, 10% human AB pooled serum, PSG). Resting CD4+ T
V. Calvanese et al. / Virology 446 (2013) 283–292 291cells were activated in U-bottom 96-well TC plates with 25 μl
human anti-CD3 and anti-CD28-coated dynabeads (Life technolo-
gies)/106 cells (48 h). Dynabeads were removed by magnetic
separation and cells seeded in HCM with 30 IU/ml rhIL-2 (NIH
AIDS Reagents Program). Cell lines and activated CD4+ cells were
infected by spinoculation (Lassen et al., 2012) with a virus amount
equivalent to 20 ng p24 or as indicated. Viral infection was
assessed by FACS analysis after 72 h. At 5 days post-infection, cells
were sorted to separate negative, single- or double-positive cells.
Sorted cell lines were treated after re-expansion for 5–15 days.
Cells were seeded in 96-well U plates and treated for 24 h before
analysis. CD4+ T cells were reseeded after sorting in 96-well U
plates with HCM in the absence of IL-2 and treated after 24 h with
drugs or human T-activator Dynabeads (48 h). Raltegravir (NARP),
TNF-α (LT), prostratin, SAHA, bryostatin-1, PMA, HMBA, PHA-M
(all from Sigma) were used in culture at indicated concentrations.
This study was conducted according to the principles expressed in
the Declaration of Helsinki. All individuals provided written
informed consent for the collection of samples and subsequent
analysis, as approved by the Institutional Review Board of the
Stanford University Blood Bank.
Flow cytometry and cell sorting
EGFP, mApple and mCherry ﬂuorescence were measured in a
MACSQuant VYB FACS analyzer (Miltenyi Biotech GmbH), FACSCalibur,
LSRII, and sorted in a FACSAriaII (all BD). Data were analyzed using
FlowJo 9.4 (TreeStar).
DNA, RNA and protein extraction, qPCR and western blot
DNA and RNA were extracted with Dneasy and RNeasy kits,
respectively (Qiagen). RNA was retrotranscribed with the high
capacity kit cDNA (Life technologies) and qPCR was performed in
the AB 7900HT Fast Real-Time PCR System, using TaqMan 2x
Master Mix and the appropriate primer-probe combinations
(Suppl Table 2, #E, F, and G). Quantiﬁcation for each qPCR reaction
was assessed by interpolation on a template dilution curve. As
normalization controls TaqMan Copy Number Reference Assay,
RNase P was used for genomic DNA and TaqMan assay GAPDH
Hs99999905_m1 for cDNA. Protein was extracted from freshly
sorted cells in RIPA buffer, followed by SDS-PAGE. Bands were
detected by chemiluminescence (ECL Hyperﬁlm Amersham) or
ﬂuorescence (Licor Odyssey) detection with anti-vif, HIV-p24 and
-α-actin (Sigma) primary antibodies.
Fluorescence microscopy
Cells were analyzed with an Axio observer Z1 microscope
(Zeiss) equipped with EC Plan Neoﬂuar 20x/0.5 PHM27, EC Plan
Neoﬂuar 40x/0.75 PH, and Plan Apo 63x/1.4 Oil DIC M27 objec-
tives, ﬁlter sets 38HE, 43HE, 45, and 50, Optovar 1.25x and 1.6x
magniﬁcation, and an Axiocam MRM REV 3.
Drug screening
Sorted GFP-only 89mASG cells-infected Jurkat cells were
expanded in culture and seeded at a 5103 cells/well density in
384-well plates (black, clear bottom, Greiner), coated with Cell-Tak
(BD). Tocriscreen total drug screening library, containing 1120
biologically active compounds dissolved in DMSO, was dispensed
in the plate at a concentration of 30 mM, using the automated
Beckman and Colter Biomek FXP robot and 50 nl VP 384 pin tool.
After 24 h culture in standard conditions, Hoechst 33342 was
automatically dispensed with Thermo multodrop 384 to each well
to evaluate total cell number of cell; plates were imaged in theInCell analyzer and analyzed with InCell Developer image analysis
software. We quantiﬁed the total area masked by the nuclear stain
and the total area of cells expressing mApple as proxies for cell
number and number of cells which had reactivated viral transcrip-
tion, respectively. On negative control wells, we calculated the
median and standard deviation and used these statistics to select
signiﬁcant conditions that differed from these expected values by
more than 2 SD.Acknowlegments
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